Henry Schein (HSIC) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Henry Schein will report Q1 2026 results before the market opens on May 5, with analysts forecasting $1.20 EPS and $3.339 billion in revenue and the company guiding FY2026 EPS to a range of $5.230–$5.370.
• In the most recent quarter Henry Schein beat estimates, reporting $1.34 EPS vs. $1.30 expected and $3.44 billion in revenue (up 7.7% YoY); analysts on average expect about $5 EPS for the current fiscal year and $6 for the next.
• The stock carries a consensus "Hold" rating and $86.92 price target amid mixed analyst actions (JPMorgan and Citi more positive), while insiders have sold roughly 105,911 shares (~$8.57M) in the last 90 days and insiders own about 0.89% of the shares.

Henry Schein (NASDAQ:HSIC - Get Free Report) is expected to be announcing its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of $1.20 per share and revenue of $3.3392 billion for the quarter. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Investors are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:00 AM ET.

Henry Schein (NASDAQ:HSIC - Get Free Report) last released its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The company had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.34 billion. During the same quarter in the previous year, the company earned $1.19 EPS. Henry Schein's quarterly revenue was up 7.7% compared to the same quarter last year. On average, analysts expect Henry Schein to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Henry Schein Stock Down 0.4%

Henry Schein stock opened at $77.20 on Tuesday. The company has a quick ratio of 0.76, a current ratio of 1.38 and a debt-to-equity ratio of 0.59. The firm's fifty day moving average is $76.74 and its 200 day moving average is $74.60. Henry Schein has a 12-month low of $61.94 and a 12-month high of $89.29. The company has a market capitalization of $8.86 billion, a PE ratio of 23.61, a PEG ratio of 2.29 and a beta of 0.88.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on HSIC. JPMorgan Chase & Co. upped their price objective on shares of Henry Schein from $78.00 to $92.00 and gave the stock an "overweight" rating in a report on Wednesday, February 25th. Wall Street Zen downgraded shares of Henry Schein from a "strong-buy" rating to a "buy" rating in a report on Sunday. UBS Group increased their target price on shares of Henry Schein from $79.00 to $87.00 and gave the company a "neutral" rating in a report on Wednesday, February 25th. Citigroup assumed coverage on shares of Henry Schein in a report on Wednesday, April 15th. They issued a "buy" rating and a $100.00 target price for the company. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Henry Schein in a report on Monday, December 29th. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $86.92.

Insider Activity at Henry Schein

In related news, Director Philip A. Laskawy sold 2,844 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $80.36, for a total transaction of $228,543.84. Following the completion of the transaction, the director owned 21,961 shares in the company, valued at approximately $1,764,785.96. This represents a 11.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kurt P. Kuehn sold 2,844 shares of the stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total transaction of $224,562.24. Following the transaction, the director owned 15,420 shares of the company's stock, valued at approximately $1,217,563.20. The trade was a 15.57% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 105,911 shares of company stock valued at $8,574,982 in the last 90 days. 0.89% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Henry Schein

Several institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC boosted its position in Henry Schein by 47.3% during the first quarter. AQR Capital Management LLC now owns 30,402 shares of the company's stock worth $2,071,000 after purchasing an additional 9,756 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Henry Schein by 1.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company's stock worth $1,155,000 after purchasing an additional 229 shares during the period. Acadian Asset Management LLC bought a new position in Henry Schein during the first quarter worth about $676,000. Cetera Investment Advisers boosted its position in Henry Schein by 12.9% during the second quarter. Cetera Investment Advisers now owns 5,561 shares of the company's stock worth $406,000 after purchasing an additional 637 shares during the period. Finally, First Trust Advisors LP boosted its position in Henry Schein by 0.8% during the second quarter. First Trust Advisors LP now owns 221,130 shares of the company's stock worth $16,154,000 after purchasing an additional 1,669 shares during the period. Institutional investors own 96.62% of the company's stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.